



Zucker rat

To ensure optimal research outcomes, continue to maintain this model on Teklad Global Diet 2018S (18% Protein Rodent Diet)

Reaching your goals in diabetes and obesity studies can be a challenge or a success depending on the reliability of your research models. The *Lep^{fa}* mutation was discovered in 1961 in the 13M outbred rat stock by Lois and Theodore Zucker. This model has since been well characterized as a model of obesity, showing commonly published metabolic symptoms including insulin resistance and hyperlipidemia.

HsdHlr:ZUCKER-*Lep^{fa}*

Molecular characteristics

- *Lep^{fa}/Lep^r* heterozygotes do not show partial expression of the *Lep^r* phenotype (51,61)
- *Lep^{fa}* is an autosomal recessive mutation on chromosome 5 (51,61)
- Missense mutation of Gln to Pro residue at position 269 of the leptin receptor (8,55)
- Leptin resistance due to decreased functional leptin receptor (3,13,47,48,54)

Metabolic characteristics

- Variable hyperglycemia (4,5,6,8,9,15,29,49,51,64,65)
- Glucose intolerance (6,8,9,51,54,60) at 11–13 weeks (49)
- Obesity (5,6,7,11,15,19,23,29,40,41,44,47,48,51,53) at four-five weeks of age (39,49)
- Hyperinsulinemia (5,6,7,9,14,15,19,22,23,24,29,37,45,49,53,54,64,65) as early as 21 days of age (51)
- Insulin-resistance (5,6,8,15,19,21,23,26,29,62,64,65) including liver (8,53), skeletal muscle (8), adipose tissue (8) and heart (60)
- Hyperphagia (5,11,12,13,15,17,19,22,23,29,49,51,53,54)
- Hyperlipidemia (4,5,6,15,19,29,30,32,38,39,43,49,51,59,60) including adipose tissue and liver (62,65)
- Decreased metabolic rate (15,17,22,29,55,63) at 8 weeks of age (58)

- Adipocyte hyperplasia (25) and hypertrophy (29)
- Enhanced energy efficiency (42,52,53,63)
- Reduced body temperature (40,51,55)
- Hypercorticotesteronemia (23,25,46,47,48,50,51)
- Increased oxidative stress (30,31,34) in heart (2,4,6) and liver (20,59)

Cardiovascular characteristics

- Borderline hypertension (1,4,5,6,7,14,18,19,24,30,31,32,34,35,40,41,55,57,65) at six weeks of age (49)
- Abnormal vascular reactivity (2,10,19,26,27,28,30,31,32,35,49,55)
- Cardiac hypertrophy (57)
- Increased mean arterial pressure (1,19,55)
- Attenuated baroreflex (1,19,32,55)

Hepatic and renal characteristics

- Elevated hepatic glycolysis (56,59)
- Impaired hepatic glycogen synthesis (3,52,53)
- Steatosis (9,16,29,58,59,65)
- Proteinuria (14,38,45)
- Reduced dopamine receptor function in the kidneys (4,5,6,41)
- Focal segment glomerulosclerosis (38,44,45)
- Elevated tubular sodium reabsorption (1,5,6,7)
- Increased urine albumin excretion (28,34,45)
- Adrenal hypertrophy (46,47,48) and hyperplasia (50)

Neurological characteristics

- Altered sympathetic and parasympathetic activity (7,19,22,23,29,30,31,32,39,43,46,51,55,63)
- Peripheral neuropathy (22,39,51,63)
- Altered neuropeptide Y regulation (22,23,29,43,46,51)
- Increased hypothalamic-pituitary-adrenal axis activity (40,48,50)

Muscular characteristics

- Diminished GLUT-4 protein translocation of glucose (21,36,49,50,60)
- Reduced microvessel density in the musculature (31,32,33)
- Remodeling of skeletal muscle microvasculature (31,32)
- Premature skeletal muscle fatigue (33)

Additional characteristics

- Infertility in homozygotes (37,43,54)
- Islet hyperplasia (14,29) and hypertrophy (29)
- Impaired thyroid hormone metabolism (19,54,64)
- Organomegaly (57)

References

1. Alonso-Galicia, M., Brands, M. W., Zappe, D. H., & Hall, J. E. (1996). Hypertension in obese Zucker rats: Role of angiotensin II and adrenergic activity. *Hypertension*, 28, 1047-1054.
2. Andrews, T. J., Laight, D. W., Ånggård, E. E., & Carrier, M. J. (2000). Investigation of Endothelial Hyperactivity in the obese Zucker rat In-situ: Reversal by vitamin E. *J Pharm Pharmacol*, 52, 83-86.
3. Arden, C., Green, A. R., Hampson, H. J., Aiston, S., Härndahl, L., Greenberg, C. C., et al. (2006). Increased sensitivity of glycogen synthesis to phosphorylase- α and impaired expression of the glycogen-targeting protein R6 in hepatocytes from insulin-resistant Zucker *fa/fa* rats. *FEBS*, 273, 1989-1999.
4. Bandy, A. A., Fazili, F. R., Marwaha, A., & Lokhandwala, M. F. (2007). Mitogen-activated protein kinase upregulation reduces renal D1 receptor affinity and G-protein coupling in obese rats. *Kidney International*, 71, 397-406.
5. Bandy, A. A., Hussain, T., & Lokhandwala, M. F. (2004). Renal dopamine D1 receptor dysfunction is acquired and not inherited in obese Zucker rats. *Am J Physiol Renal Physiol*, 287, F109-F116.
6. Bandy, A. A., Marwaha, A., Tallam, L. S., & Lakhandwala, M. F. (2005). Tempol reduces oxidative stress, improves insulin sensitivity, decreases renal dopamine D1 receptor hyperphosphorylation, and restores D1 receptor-G-Protein coupling and function in obese Zucker rats. *Diabetes*, 54, 2219-2226.
7. Becker, M., Umrani, D., Lokhandwala, M. F., & Hussain, T. (2003). Increased renal angiotensin II AT1 receptor function in obese Zucker rat. *Clinical and Experimental Hypertension*, 25, 35-47.
8. Berthiaume, N., & Zinker, B. A. (2002). Metabolic responses in a model of insulin resistance: Comparison between oral glucose and meal tolerance tests. *Metabolism*, 51, 595-598.
9. Blomqvist, M., Carrier, M., Andrews, T., Pettersson, K., Månsson, J.-E., Rynmark, B.-M., et al. (2005). In vivo administration of the C16:0 fatty acid isoform of sulfatide increases pancreatic sulfatide and enhances glucosestimulated insulin secretion in Zucker fatty (*fa/fa*) rats. *Diabetes/Metabolism Research and Reviews*, 21, 158-166.
10. Bohlen, H. G. (2004). Protein kinase β in Zucker obese rats compromises oxygen and flow-mediated regulation of nitric oxide formation. *Am J Physiol Heart Circ Physiol*, 286, 492-497.
11. Boules, M., Cusack, B., Zhao, L., Fauq, A., McCormick, D. J., & Richelson, E. (2000). A novel neurotensin peptide analog given extracranially decreases food intake and weight in rodents. *Brain Research*, 865, 35-44.
12. Brown, L. M., Benoit, S. C., Woods, S. C., & Clegg, D. J. (2007). Intraventricular (i3vt) ghrelin increases good intake in fatty Zucker rats. *Peptides*, 28, 612-616.
13. Brunner, L., Nick, H.-P., Cumin, F., Chiesi, M., Baum, H.-P., Whitebread, S., et al. (1997). Leptin is a physiologically important regulator of food intake. *International Journal of Obesity*, 21, 1152-1160.
14. Buckingham, R. E., Al-Barazani, K. A., Toseland, C. D. N., Slaughter, M., Connor, S. C., West, A., et al. (1998). Peroxisome proliferator-activated receptor- γ agonist, rosiglitazone, protects against nephropathy and pancreatic islet abnormalities in Zucker fatty rats. *Diabetes*, 47, 1326-1334.
15. Cai, X. J., Lister, C. A., Buckingham, R. E., Pickavance, L., Wilding, J., Arch, J. R. S., et al. (2000). Down-regulation of orexin gene expression by severe obesity in the rats: studies in Zucker fatty and Zucker diabetic fatty rats and effects of rosiglitazone. *Molecular Brain Research*, 77, 131-137.
16. Charu, T., Prescott, L., & Koneru, B. (1998). Critical preservation injury in rat fatty liver is to hepatocytes, not sinusoidal lining cells. *Transplantation*, 65, 167-172.
17. Choi, S., Noh, J., Hirose, R., Ferrell, L., Bedolli, M., Roberts, J. P., et al. (2005). Mild hypothermia provides significant protection against ischemia/reperfusion injury in livers of obese and lean rats. *Ann Surg*, 241, 470-476.
18. Cumin, F., Baum, H.-P., de Gasparo, M., & Levens, N. (1997). Removal of endogenous leptin from the circulation by the kidney. *International Journal of Obesity*, 21, 495-504.
19. D'Angelo, G., Mintz, J. D., Tidwell, J. E., Schreihofner, A. M., Pollock, D. M., & Stepp, D. W. (2006). Exaggerated cardiovascular stress responses and impaired β -adrenergic-mediated pressor recovery in obese Zucker rats. *Hypertension*, 48, 1109-1115.
20. Dikdan, G. S., Saba, S. C., dela Torre, A. N., Roth, J., Wang, S., & Koneru, B. (2004). Role of oxidative stress in the increased activation of signal transducers and activators of transcription-3 in the fatty livers of obese Zucker rats. *Surgery*, 136, 677-685.
21. Dokken, B. B., & Henriksen, E. J. (2006). Chronic selective glucagon synthase kinase-3 inhibition enhances glucose disposal and muscle insulin action in prediabetic obese Zucker rats. *Am J Physiol Endocrinol Metab*, 291, 207-213.
22. Dryden, S., Frankish, H. M., Wang, Q., Pickavance, L., & Williams, G. (1996). The serotonergic agent fluoxetine reduces neuropeptide Y levels and neuropeptide Y secretion in the hypothalamus of lean and obese rats. *Neuroscience*, 72, 557-566.
23. Dryden, S., Pickavance, L., Frankish, H. M., & Williams, G. (1995). Increased neuropeptide Y secretion in the hypothalamic paraventricular nucleus of obese (*fa/fa*) Zucker rats. *Brain Research*, 690, 185-188.
24. Duarte, J., Martinez, A., Bermejo, A., Vera, B., Gámez, M. J., Cabo, P., et al. (1999). Cardiovascular effects of captopril and enalapril in obese Zucker rats. *European Journal of Pharmacology*, 365, 225-232.
25. Edwards, E., King, J. A., & Fray, J. (2000). Hypertension and insulin resistant models have divergent propensities in learned helpless behavior in rodents. *AJH*, 13, 659-665.
26. Erdős, B., Snipes, J. A., Kis, B., Miller, A. W., & Busija, D. W. (2004). Vasoconstrictor mechanisms in the cerebral circulation are unaffected by insulin resistance. *Am J Physiol Regul Integr Comp Physiol*, 287, 1456-1461.
27. Erdős, B., Snipes, J. A., Miller, A. W., & Busija, D. W. (2004). Cerebrovascular dysfunction in Zucker obese rats is mediated by oxidative stress and protein kinase C. *Diabetes*, 53, 1352-1359.
28. Erdős, B., Snipes, J. A., Tulbert, C. D., Katakam, P., Miller, A. W., & Busija, D. W. (2006). Rosuvastatin improves cerebrovascular function in Zucker obese rats by inhibiting NAD(P)H oxidase-dependent superoxide production. *Am J Physiol Heart Circ Physiol*, 290, H1264-H1270.
29. Ferrari, B., Arnold, M., Carr, R. D., Langhans, W., Pacini, G., Bodvarsdóttir, T. B., et al. (2005). Subdiaphragmatic vagal denervation affects body weight gain and glucose metabolism in obese male Zucker (*fa/fa*) rats. *Am J Physiol Regul Integr Comp Physiol*, 289, 1027-1034.
30. Frisbee, J. C. (2004). Enhanced arteriolar α -adrenergic constriction impairs dilator responses and skeletal muscle perfusion in obese Zucker rats. *J Appl Physiol*, 97, 764-772.
31. Frisbee, J. C. (2003). Impaired skeletal muscle perfusion in obese Zucker rats. *Am J Physiol Regul Integr Comp Physiol*, 285, 1124-1134.
32. Frisbee, J. C. (2003). Remodeling of the skeletal muscle microcirculation increases resistance of perfusion in obese Zucker rats. *Am J Physiol Heart Circ Physiol*, 285, 104-111.
33. Frisbee, J. C., Samora, J. B., Peterson, J., & Bryner, R. (2006). Exercise training blunts microvascular rarefaction in the metabolic syndrome. *Am J Physiol Heart Circ Physiol*, 291, 2483-2492.
34. Frisbee, J. C., & Stepp, D. W. (2001). Impaired NO-dependent dilation of skeletal muscle arterioles in hypertensive diabetic obese Zucker rats. *Am J Physiol Heart Circ Physiol*, 281, 1304-1311.
35. Fulton, D. M., Harris, M. B., Kemp, B. E., Venema, M. B., Marrero, M. B., & Stepp, D. W. (2004). Insulin resistance does not diminish eNOS expression, phosphorylation, or binding to HSP-90. *Am J Physiol Heart Circ Physiol*, 287, H2384-93.
36. Fürsinn, C., Noe, C., Herdlicka, R., Roden, M., Nowotny, P., Leighton, B., et al. (1997). More marked stimulation by lithium than insulin of the gluco-genic pathway in rat skeletal muscle. *Am J Physiol Endocrinol Metab*, 273, 514-520.
37. Fürsinn, C., Nowotny, P., Brunmair, B., Gras, F., Roden, M., Waldhäusl, W., et al. (2002). Thiazolidinediones influence plasma steroids of male obese Zucker rats. *Endocrinology*, 143, 327-330.
38. Gassler, N., Elger, M., Kränzlin, B., Kriz, W., & Gretz, N. (2001). Podocyte injury underlies the progression of focal segmental glomerulosclerosis in the *fa/fa* Zucker rat. *Kidney International*, 60, 106-116.
39. Hakkak, R., Holley, A. W., MacLeod, S. L., Simpson, P. M., Fuchs, G. J., Jo, C. H., et al. (2005). Obesity promotes 7,12-dimethylbenz(a)anthracene-induced mammary tumor development in female Zucker rats. *Breast Cancer Research*, 7, 627-633.
40. Heinrichs, S. C., Joppa, M., Lapsansky, J., Jeske, K., Nelson, R., & de Souza, E. (2001). Selective stimulatory actions of corticotrophin-releasing factor ligands on correlates of energy balance. *Physiology and Behavior*, 74, 5-13.
41. Hussain, T., Beheray, S. A., & Lokhandwala, M. F. (1999). Defective dopamine receptor function in proximal tubules of obese Zucker rats. *Hypertension*, 34, 1091-1096.
42. Jarosz, P. A. (2007). The effect of Kappa opioid receptor antagonism on energy expenditure in the obese Zucker rat. *Biological Research for Nursing*, 8, 294-299.
43. Keen-Rhinehart, E., Kalra, S. P., & Kalra, P. S. (2004). Leptin-receptor gene transfer into the arcuate nucleus of female fatty Zucker rats using recombinant adeno-associated viral vectors stimulates the hypothalamopituitary-gonadal axis. *Biology of Reproduction*, 71, 266-272.
44. Kim, C. H., Vaziri, N. D., & Rodriguez-Iturbe, B. (2007). Integrin expression and H₂O₂ production in circulating and splenic leukocytes of obese rats. *Obesity*, 15, 2209-2216.
45. Li, Z., Rodriguez-Iturbe, B., Ni, Z., Shahkarami, A., Sepassi, L., & Vaziri, N. D. (2005). Effect of hereditary obesity on renal expressions of NO synthase, caveolin-1, Akt, guanylate cyclase, and calmodulin. *Kidney International*, 68, 2766-2772.
46. Livingstone, D. E. W., Jones, G. C., Smith, K., Jamieson, P. M., Andrew, R., Kenyon, C. J., et al. (2000). Understanding the role of glucocorticoids in obesity: Tissuespecific alterations of corticosterone metabolism in obese Zucker rats. *Endocrinology*, 141, 560-563.
47. Livingstone, D. E. W., Kenyon, C. J., & Walker, B. R. (2000). Mechanisms of dysregulation of 11 β -hydroxysteroid dehydrogenase type 1 in obese Zucker rats. *Endocrinology*, 147, 533-539.
48. Livingstone, D. E. W., & Walker, B. R. (2003). Is 11 β -Hydroxysteroid Dehydrogenase type 1 a therapeutic target? Effects of Carbenoxolone in lean and obese Zucker rats. *JPET*, 203, 167-172.
49. Maher, M. A., Banz, W. J., & Zemel, M. B. (1995). Variations of blood pressures in lean Zucker rats fed low or high fat diets. *J Nutr*, 125, 2618-2622.
50. Mattsson, C., Lai, M., Noble, J., McKinney, E., Yau, J. L., Seckl, J. R., et al. (2003). Obese Zucker rats have reduced mineralocorticoid receptor and 11 β -Hydroxysteroid Dehydrogenase type 1 expression in the hippocampus-implication for dysregulation of the hypothalamic-pituitary-adrenal axis in obesity. *Endocrinology*, 144, 2997-3003.
51. McNeill, J. H. (Ed.). (1999). *Experimental Models of Diabetes*. CRC Press: Boca Raton.
52. Obeid, O. A., Jamal, Z. M., Hwalla, N., & Emery, P. W. (2006). The effect of glutamine and dihydroxyacetone supplementation on food intake, weight gain, and postprandial glycogen synthesis in female Zucker rats. *Nutrition*, 22, 794-801.
53. Obeid, O. A., Powell-Tuck, J., & Emery, P. W. (2000). The postprandial rates of glycogen and lipid synthesis in lean and obese female Zucker rats. *International Journal of Obesity*, 24, 508-513.

54. Östman, E. M., Elmståhl, H. G. M., Molin, G., Lundquist, I., & Björck, I. M. E. (2005). A diet based on wheat bread baked with lactic acid improves glucose tolerance in hyperinsulinemic Zucker (*fa/fa*) rats. *Journal of Cereal Science*, 42, 300-308.
55. Overton, J. M., Williams, T. D., Chambers, J. B., & Rashotte, M. E. (2001). Cardiovascular and metabolic responses to fasting and thermoneutrality are conserved in obese Zucker rats. *Am J Physiol Regulatory Integrative Comp Physiol*, 280, 1007-1015.
56. Payne, V. A., Arden, C., Lange, A. J., & Agius, L. (2007). Contributions of glucokinase and phosphofructokinase-2/fructose biphosphatase-2 to the elevated glycolysis in hepatocytes from Zucker *fa/fa* rats. *Am J Physiol Regul Integr Comp Physiol*, 293, 618-625.
57. Ren, J., Walsh, M. F., Jefferson, L., Natavio, M., Ilg, K. J., Sowers, J. R., et al. (2000). Basal and ethanol-induced cardiac contractile response in lean and obese Zucker rat hearts. *J Biomed Sci*, 7, 390-400.
58. Selzner, M., & Clavier, P.-A. (2000). Failure of regeneration of the steatotic liver: disruption at two different levels in the regeneration pathway. *Hepatology*, 31, 35-42.
59. Serkova, N. J., Jackman, M., Brown, J. L., Liu, T., Hirose, R., Roberts, J. P., et al. (2006). Metabolic profiling of livers and blood from obese Zucker rats. *Journal of Hepatology*, 44, 956-062.
60. Sidell, R. J., Cole, M. A., Draper, M. J., Desrois, M., Buckingham, R. E., & Clarke, K. (2002). Thiazolidinedione treatment normalizes insulin resistance and ischemic injury in the Zucker fatty rat heart. *Diabetes*, 51, 1110-1117.
61. Strobl, W., Knerer, B., Gratzl, R., Arbeiter, K., Lin-Lee, Y.-C., & Patsch, W. (1993). Altered regulation of apolipoprotein A-IV gene expression in the liver of the genetically obese Zucker rat. *J Clin Invest*, 92, 1766-1773.
62. Thyfault, J. P., Cree, M. G., Zheng, D., Zwetsloot, J. J., Tapscott, E. B., Koves, T. R., et al. (2007). Contraction of insulin-resistant muscle normalizes insulin action in association with increased mitochondrial activity and fatty acid catabolism. *Am J Physiol Cell Physiol*, 292, C729-C739.
63. Tonello, C., Giordano, A., Cozzi, V., Cinti, S., Stock, M. J., Carruba, M. O., et al. (1999). Role of sympathetic activity in controlling the expression of vascular endothelial growth factor in brown fat cells of lean and genetically obese rats. *FEBS Letters*, 442, 167-172.
64. Torrance, C. J., Devente, J. E., Jones, J. P., & Dohm, C. L. (1997). Effects of thyroid hormone on GLUT4 glucose transporter gene expression and NIDDM in rats. *Endocrinology*, 138, 1204-1214.
65. Tovar, A. R., Torre-Villalvazo, I., Ochoa, M., Elias, A. L., Ortiz, V., Aguilar-Salinas, C. A., et al. (2005). Soy protein reduces hepatic lipotoxicity in hyperinsulinemic obese Zucker *fa/fa* rats. *J Lipid Res*, 46, 1823-1832.

Contact us

North America 800.793.7287 EU and Asia envigo.com/contactus info@envigo.com



Envigo RMS Division, 8520 Allison Pointe Blvd., Suite 400, Indianapolis, IN 46250, United States

© 2016 Envigo.

RMS-1116-EU-01-PS-226